Postherpetic Neuralgia (PHN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Postherpetic Neuralgia (PHN) Therapeutics - Pipeline Assessment
and Market Forecasts to 2017
Published on June 2011

Report Summary

Postherpetic Neuralgia (PHN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Postherpetic Neuralgia (PHN) Therapeutics - Pipeline
Assessment and Market Forecasts to 2017'. The report is an essential source of information and analysis on the global Postherpetic
Neuralgia Therapeutics market. The report identifies the key trends shaping and driving the global Postherpetic Neuralgia
Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to
significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the
pipeline products within the global Postherpetic Neuralgia Therapeutics sector. This report is built using data and information sourced
from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Postherpetic Neuralgia Therapeutics market. Its scope
includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Postherpetic Neuralgia Therapeutics market
revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by
seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Postherpetic Neuralgia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a
qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the
Postherpetic Neuralgia Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Postherpetic Neuralgia Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by
identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Postherpetic Neuralgia Therapeutics
market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to
impact the global Postherpetic Neuralgia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of
various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive

Postherpetic Neuralgia (PHN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 1/8


advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities
for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Postherpetic Neuralgia Therapeutics market landscape' ' Identify, understand and capitalize.

Table of Content

1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Postherpetic Neuralgia Therapeutics - Introduction 7
2.1 Overview 7
2.2 Etiology and Pathophysiology 7
2.3 Epidemiology 7
2.4 Symptoms 8
2.5 Diagnosis 8
2.6 Treatment and Management Pattern 8
2.7 GlobalData Pipeline Report Guidance 10
3 Postherpetic Neuralgia Therapeutics - Market Characterization 11
3.1 Postherpetic Neuralgia Therapeutics Market Size (2005-2010) - Global 11
3.2 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017) - Global 12
3.3 Postherpetic Neuralgia Therapeutics Market Size (2005-2010): The US 13
3.4 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): The US 14
3.5 Postherpetic Neuralgia Therapeutics Market (2005-2010): France 15
3.6 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): France 16
3.7 Postherpetic Neuralgia Therapeutics Market (2005-2010): Germany 17
3.8 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): Germany 18
3.9 Postherpetic Neuralgia Therapeutics Market (2005-2010): Italy 19
3.10 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): Italy 20
3.11 Postherpetic Neuralgia Therapeutics Market (2005-2010): Spain 21
3.12 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): Spain 22
3.13 Postherpetic Neuralgia Therapeutics Market (2005-2010): The UK 23
3.14 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): The UK 24
3.15 Postherpetic Neuralgia Therapeutics Market (2005-2010): Japan 25
3.16 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): Japan 26
3.17 Drivers and Barriers for the Postherpetic Neuralgia Therapeutics Market 27
3.17.1 Drivers for the Postherpetic Neuralgia Therapeutics Market 27
3.17.2 Barriers for the Postherpetic Neuralgia Therapeutics Market 27
3.18 Opportunity and Unmet Need Analysis 28
3.19 Key Takeaway 28
4 Postherpetic Neuralgia Therapeutics - Competitive Assessment 29
4.1 Overview 29
4.2 Strategic Competitor Assessment 29
4.3 Product Profile for the Major Marketed Products in the Postherpetic Neuralgia Therapeutics Market 30
4.3.1 Lidoderm (lidocaine patch 5%) 30



4.3.2 Neurontin (gabapentin) 31
4.3.3 Lyrica (pregabalin) 32
4.3.4 Qutenza (capsaicin 8% patch) 34
4.3.5 Gralise (gabapentin) 35
4.4 Key Takeaway 35
5 Postherpetic Neuralgia Therapeutics - Pipeline Assessment 36
5.1 Overview 36
5.2 Strategic Pipeline Assessment 36
5.3 Postherpetic Neuralgia Therapeutics Pipeline ' Pipeline by Phases of Development 36
5.3.1 Postherpetic Neuralgia Therapeutics ' Phase III Pipeline 37
5.3.2 Postherpetic Neuralgia Therapeutics ' Phase II Pipeline 37
5.3.3 Postherpetic Neuralgia Therapeutics ' Preclinical Pipeline 37
5.4 Postherpetic Neuralgia Therapeutics Market ' Pipeline by Mechanism of Action 38
5.5 Technology Trends Analytical Framework 39
6 Postherpetic Neuralgia Therapeutics - Clinical Trials Mapping 41
6.1 Clinical Trials by Country (US, EU5 & Japan) 41
6.2 Clinical Trials by Phase 42
6.3 Clinical Trials by Trial Status 43
6.4 Prominent Sponsors 44
6.5 Key Companies Participating in Therapeutics Clinical Trials 46
7 Postherpetic Neuralgia Therapeutics - Stategic Assessment 47
7.1 Key Events Impacting on the Future Market 47
7.2 Postherpetic Neuralgia Therapeutics: Implications for Future Market Competition 48
8 Postherpetic Neuralgia Therapeutics - Future Players 49
8.1 Introduction 49
8.2 Company Profiles 50
8.2.1 Pfizer Inc. 50
8.2.2 Adolor Corp. 52
8.2.3 Allergan Inc. 54
8.2.4 GlaxoSmithKline Plc 56
8.2.5 Durect Corp. 58
8.2.6 EpiCept Corporation 60
8.2.7 Bial Group 61
8.2.8 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 61
8.2.9 Xenon Pharmaceuticals Inc. 63
8.2.10 KAI Pharmaceuticals Inc. 64
8.2.11 Other Companies in the Postherpetic Neuralgia Therapeutics Market 64
9 Postherpetic Neuralgia Therapeutics - Licensing and Partnership Deals 66
10 Postherpetic Neuralgia Therapeutics - Appendix 68
10.1 Market Definitions 68
10.2 Abbreviations 68
10.3 Methodology 69
10.3.1 Coverage 69
10.3.2 Secondary Research 70
10.3.3 Forecasting 70
10.3.4 Primary Research 73
10.3.5 Expert Panels Validation 73
10.4 Contact Us 73



10.5 Disclaimer 73
10.6 Bibliography 74

1.1 List of Tables

Table 1: Postherpetic Neuralgia Therapeutics Market, Global, Revenue($m), 2005-2010 11
Table 2: Postherpetic Neuralgia Therapeutics Market, Global, Forecast($m), 2010-2017 12
Table 3: Postherpetic Neuralgia Therapeutics Market, The US, Revenue($m), 2005-2010 13
Table 4: Postherpetic Neuralgia Therapeutics Market, The US, Forecast($m), 2010-2017 14
Table 5: Postherpetic Neuralgia Therapeutics Market, France, Revenue($m), 2005-2010 15
Table 6: Postherpetic Neuralgia Therapeutics Market, France, Forecast($m), 2010-2017 16
Table 7: Postherpetic Neuralgia Therapeutics Market, Germany, Revenue($m), 2005-2010 17
Table 8: Postherpetic Neuralgia Therapeutics Market, Germany, Forecast ($m), 2010-2017 18
Table 9: Postherpetic Neuralgia Therapeutics Market, Italy, Revenue ($m), 2005-2010 19
Table 10: Postherpetic Neuralgia Therapeutics Market, Italy, Forecast ($m), 2010-2017 20
Table 11: Postherpetic Neuralgia Therapeutics Market, Spain, Revenue ($m), 2005-2010 21
Table 12: Postherpetic Neuralgia Therapeutics Market, Spain, Forecast ($m), 2010-2017 22
Table 13: Postherpetic Neuralgia Therapeutics Market, The UK, Revenue ($m), 2005-2010 23
Table 14: Postherpetic Neuralgia Therapeutics Market, The UK, Forecast ($m), 2010-2017 24
Table 15: Postherpetic Neuralgia Therapeutics Market, Japan, Revenue ($m), 2005-2010 25
Table 16: Postherpetic Neuralgia Therapeutics Market, Japan, Forecast ($m), 2010-2017 26
Table 17: Postherpetic Neuralgia Therapeutics ' Phase III Pipeline, 2011 37
Table 18: Postherpetic Neuralgia Therapeutics ' Phase II Pipeline, 2011 37
Table 19: Postherpetic Neuralgia Therapeutics ' Preclinical Pipeline, 2011 37
Table 20: Postherpetic Neuralgia Therapeutics, Clinical Trials by Country,2011 41
Table 21: Postherpetic Neuralgia Therapeutics, Global, Clinical Trials by Phase of Development, 2011 42
Table 22: Postherpetic Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2011 43
Table 23: Postherpetic Neuralgia Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 44
Table 24: Postherpetic Neuralgia Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 45
Table 25: Postherpetic Neuralgia Therapeutics, Global, Clinical Trials by Top Companies, 2011 46
Table 26: Pfizer Inc. - CNS Pipeline Portfolio, 2011 51
Table 27: Pfizer Inc. - Deals, 2011 52
Table 28: Adolor Corp. ' CNS Pipeline Portfolio, 2011 53
Table 29: Adolor Adolor Corp. - Deals, 2009-2010 53
Table 30: Allergan Inc. ' CNS Pipeline Portfolio, 2011 55
Table 31: Avanir Pharmaceuticals - Deals, 2010-2011 55
Table 32: GlaxoSmithKline plc ' CNS Pipeline Portfolio, 2011 57
Table 33: GlaxoSmithKline Plc ' Deals, 2010-2011 58
Table 34: Durect Corp. ' CNS Pipeline Portfolio, 2011 59
Table 35: Durect Corp. ' Deals, 2010'2011 59
Table 36: EpiCept Corporation ' CNS Pipeline Portfolio, 2011 60
Table 37: EpiCept Corporation ' Deals, 2010 60
Table 38: Bial Group ' CNS pipeline products, 2011 61
Table 39: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. - CNS Pipeline Portfolio, 2011 62
Table 40: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.-Deals, 2009-2010 62
Table 41: Xenon Pharmaceuticals Inc. ' CNS Pipeline Portfolio, 2011 63
Table 42: Xenon Pharmaceuticals Inc. ' Deals, 2009-2010 63
Table 43: KAI Pharmaceuticals Inc. ' CNS Pipeline Portfolio, 2011 64



Table 44: Other Companies in the Pipeline, 2011 64
Table 45: Licensing and Partnership Deals, 2010-2011 66

1.2 List of Figures

Figure 1: Treatment Approach for Postherpetic Neuralgia 9
Figure 2: Postherpetic Neuralgia Therapeutics Market, Global, Revenue($m), 2005-2010 11
Figure 3: Postherpetic Neuralgia Therapeutics Market, Global, Forecast ($m), 2010-2017 12
Figure 4: Postherpetic Neuralgia Therapeutics Market, The US, Revenue($m), 2005-2010 13
Figure 5: Postherpetic Neuralgia Therapeutics Market, The US, Forecast($m), 2010-2017 14
Figure 6: Postherpetic Neuralgia Therapeutics Market, France, Revenue($m), 2005-2010 15
Figure 7: Postherpetic Neuralgia Therapeutics Market, France, Forecast($m), 2010-2017 16
Figure 8: Postherpetic Neuralgia Therapeutics Market, Germany, Revenue($m), 2005-2010 17
Figure 9: Postherpetic Neuralgia Therapeutics Market, Germany, Forecast ($m), 2010-2017 18
Figure 10: Postherpetic Neuralgia Therapeutics Market, Italy, Revenue ($m), 2005-2010 19
Figure 11: Postherpetic Neuralgia Therapeutics Market, Italy, Forecast ($m), 2010-2017 20
Figure 12: Postherpetic Neuralgia Therapeutics Market, Spain, Revenue ($m), 2005-2010 21
Figure 13: Postherpetic Neuralgia Therapeutics Market, Spain, Forecast ($m), 2010-2017 22
Figure 14: Postherpetic Neuralgia Therapeutics Market, The UK, Revenue ($m), 2005-2010 23
Figure 15: Postherpetic Neuralgia Therapeutics Market, The UK, Forecast ($m), 2010-2017 24
Figure 16: Postherpetic Neuralgia Therapeutics Market, Japan, Revenue ($m), 2005-2010 25
Figure 17: Postherpetic Neuralgia Therapeutics Market, Japan, Forecast ($m), 2010-2017 26
Figure 18: Opportunity and Unmet Need in the Postherpetic Neuralgia Therapeutics Market, 2010 28
Figure 19: Strategic Competitor Assessment of the Major Marketed Products for Postherpetic Neuralgia, 2011 29
Figure 20: Postherpetic Neuralgia Therapeutics Pipeline by Phase of Development, 2011 36
Figure 21: Postherpetic Neuralgia Therapeutics Market ' Pipeline by Mechanism of Action, 2011 38
Figure 22: Technology Trends Analytic Framework of the Postherpetic Neuralgia Therapeutics Pipeline, 2011 39
Figure 23: Technology Trends Analytic Framework of the Postherpetic Neuralgia Therapeutics Pipeline - Description, 2011 40
Figure 24: Postherpetic Neuralgia Therapeutics - Clinical Trials by Country, 2011 41
Figure 25: Postherpetic Neuralgia Therapeutics, Global, Clinical Trials by Phase of Development, 2011 42
Figure 26: Postherpetic Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2011 43
Figure 27: Postherpetic Neuralgia Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 44
Figure 28: Postherpetic Neuralgia Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 45
Figure 29: Postherpetic Neuralgia Therapeutics, Global, Clinical Trials by Top Companies, 2011 46
Figure 30: Drivers and Barriers of the Postherpetic Neuralgia Therapeutics Market 47
Figure 31: Implications for Future Market Competition in the Postherpetic Neuralgia Therapeutics Market, 2011 48
Figure 32: Postherpetic Neuralgia Therapeutics ' Pipeline by Company, 2011 49
Figure 33: GlobalData Market Forecasting Model 72

Companies Mentioned
Pfizer Inc.
Adolor Corp.
Allergan Inc.
GlaxoSmithKline Plc
Durect Corp.
EpiCept Corporation
Bial Group
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.



Xenon Pharmaceuticals Inc.
KAI Pharmaceuticals Inc.


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Postherpetic Neuralgia (PHN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Postherpetic Neuralgia (PHN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Postherpetic Neuralgia (PHN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017